NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

Glioblastoma mutates so the neoantigens present on it are not the same after recurrence. So they made a new batch of DCVax after subsequent resection. I wouldn't call it a booster since the composition of the vaccine isn't same as the first tranche of doses. They made the vaccine from the mutated recurrent tumor.

From the compassionate use we know now that rGBM patients can live even longer than in the Landmark PIII trial if they have another set of vaccine made from the further mutated recurrent tumor. That's pretty profound as it expands survival significantly thus the cost benefit analysis (QALY) used for insurance reimbursement. There's really nothing stopping DCVax approval.